Colon Cancer, Metastatic Cancer, Organoids
Conditions
Brief summary
Eighty patients with RAS/RAF wild-type metastatic right colon cancer will be enrolled and undergo a fresh biopsy of tumor lesion before the standard treatment of chemotherapy. The investigators will establish organoids from the pre-treatment biopsies. Organoids will be exposed to the chemotherapy drugs or chemotherapy drugs combined with cetuximab used for each patient. The sensitivity of chemotherapy drugs or combined cetuximab will be tested in the organoids model. Chemotherapy strategies including 5-fluorouracil only, irinotecan only, oxaliplatin only, FOLFOX, and FOLFIRI. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) model of colon cancer to predict the clinical efficacy of combined treatment of cetuximab, which to formulate the best therapy regimen for each given patient.
Detailed description
Investigators hypothesize that the cetuximab sensitivity test results on patient-derived organoids can be used to predict the treatment selection of patients with RAS/RAF wild-type metastatic right colon cancer. Objectives 1. To assess the effective rate of cetuximab target therapy on RAS/RAF wild-type right colon cancer 2. To assess the consistency of organoid chemotherapy sensitivity and clinical chemotherapy efficacy 3. To assess the consistency of organoid cetuximab sensitivity and clinical cetuximab efficacy The following points will be addressed: 1. The biopsy tissue of RAS/RAF wild-type metastatic right colon cancer will be collected and subject to ex vivo 3-D culture to establish patient-derived tumor organoids, which will be used for the drug sensitivity test. 2. Enrolled patients will treat with chemotherapy or chemotherapy combined target therapy. The medication regime and treatment cycle will be decided based on the clinical guideline and evidence-based medicine. 3. The patient-derived organoid-based drug sensitivity test will compare with clinical treatment data of chemotherapy or chemotherapy combined target therapy, followed by correlation analysis.
Interventions
PROCEDURETumor biopsy
Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
Sponsors
Fudan University
D1 Medical Technology (Shanghai) Co., Ltd, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age from 18 to 70 years old, no gender limit 2. The primary tumor is located in the right colon, including the ileocecal area, ascending colon, liver flexure, and the right part of the transverse colon. 3. Pathologically proved primary intestinal tumor with simultaneous / metachronous metastasis 4. Molecular pathology confirmed as RAS/RAF wild type 5. Can tolerate and cooperate with the completion of chemotherapy and targeted therapy 6. Tissues can be obtained through puncture or colonoscopy for organoid culture 7. Complete clinical data, as well as efficacy evaluation data, can be obtained
Exclusion criteria
1. Less than 18 years of age or more than 70 years of age 2. The primary tumor is located in the left colon or rectum 3. Pathology results can't confirm as colon cancer 4. RAS and RAF are mutant confirmed by molecular pathology 5. Refuse to cooperate and complete the treatment, or there is a contraindication for chemotherapy or targeted therapy 6. No available metastatic lesions tissue 7. Unable to obtain complete clinical data or efficacy evaluation data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes | 2021.05-2023.05 | The drug sensitivity tests on patient-derived tumor organoids will compare with the clinical response of the chemo- or targeted therapy treatment. The correlation of organoids sensitivity and patient response will be evaluated. |
Countries
China
Contacts
Primary ContactHanqing Lin, Dr.
Backup ContactChunyan Cheng, Dr.
Outcome results
None listed